1. Home
  2. AIN vs RAPP Comparison

AIN vs RAPP Comparison

Compare AIN & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Albany International Corporation

AIN

Albany International Corporation

HOLD

Current Price

$62.72

Market Cap

2.2B

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$45.10

Market Cap

1.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIN
RAPP
Founded
1895
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Textiles
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
AIN
RAPP
Price
$62.72
$45.10
Analyst Decision
Hold
Strong Buy
Analyst Count
4
6
Target Price
$60.25
$48.50
AVG Volume (30 Days)
255.4K
302.9K
Earning Date
04-30-2026
05-08-2026
Dividend Yield
1.93%
N/A
EPS Growth
N/A
24.34
EPS
1.14
N/A
Revenue
$1,054,132,000.00
N/A
Revenue This Year
$1.20
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$53.75
N/A
Revenue Growth
7.29
N/A
52 Week Low
$41.15
$13.86
52 Week High
$77.00
$46.72

Technical Indicators

Market Signals
Indicator
AIN
RAPP
Relative Strength Index (RSI) 25.15 65.49
Support Level $53.83 $33.54
Resistance Level $64.04 N/A
Average True Range (ATR) 2.87 2.44
MACD -1.81 0.22
Stochastic Oscillator 14.00 94.69

Price Performance

Historical Comparison
AIN
RAPP

About AIN Albany International Corporation

Albany International Corp is a textiles and materials processing company specializing in engineered fabrics and composite components and assemblies for the paper, industrial manufacturing and aerospace industries. It operates through two segments: Machine Clothing, which produces custom-designed fabrics and high-speed process belts for paper, paperboard, tissue, towel and pulp, as well as engineered fabrics for other industrial applications, and contributes the majority of revenue; and Albany Engineered Composites, which provides engineered composite parts for the aerospace and defense industries. The company generates revenue from the United States, Switzerland, Brazil, China, Mexico, France and other areas.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: